Another company has elected to add bitcoin (BTC) to its balance sheet.
Christian Angermayer, the chairman of Germany-based biopharmaceutical company atai Life Sciences (ATAI) announced today that the firm would develop its own bitcoin treasury strategy.
STORY CONTINUES BELOW
“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success,” Angermayer wrote on Substack.
The company will initially invest $5 million in bitcoin, Angermayer said, while holding enough cash, short-term securities and public equity for operational expenses into 2027.
The pharmaceutical firm is the latest in a long line of corporations which have sought to replicate Michael Saylor’s bitcoin treasury strategy.
ATAI briefly surged when the news broke but is now down 2.8% for the day. After briefly topping $87,000 overnight, bitcoin has been in quick retreat, now changing hands at $83,900, lower by about 1% over the past 24 hours.
